Condensed Consolidated Statements of Operations - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating expenses:
Research and development	[1]	$ 50,803	$ 53,813	$ 101,920	$ 105,154
General and administrative	[2]	16,603	10,310	30,755	19,052
Total operating expenses		67,406	64,123	132,675	124,206
Interest expense		3,788	1,580	7,581	3,197
Interest income		(942)	0	(1,708)	0
Other expense (income), net		121	(21)	(584)	268
Loss before income taxes		(70,373)	(65,682)	(137,964)	(127,671)
Income tax expense		195	88	508	233
Net loss		$ (70,568)	$ (65,770)	$ (138,472)	$ (127,904)
Net loss per common share — basic and diluted (in USD per share)		$ (0.79)	$ (0.99)	$ (1.68)	$ (1.97)
Weighted average common shares outstanding — basic and diluted (in shares)		88,798,398	66,666,876	82,667,061	64,997,698
Research and development
Costs allocated from RSL, RSI, and RSG		$ 26	$ 246	$ 51	$ 2,434
General and administrative
Costs allocated from RSL, RSI, and RSG		$ 224	$ 949	$ 422	$ 2,174

[1] Includes $26 and $246 of costs allocated from RSL, RSI, and RSG during the three months ended September 30, 2019 and 2018, respectively, and $51 and $2,434 of costs allocated from RSL, RSI, and RSG during the six months ended September 30, 2019 and 2018, respectively. Also includes share-based compensation expense (see Note 10).

[2] Includes $224 and $949 of costs allocated from RSL, RSI, and RSG during the three months ended September 30, 2019 and 2018, respectively, and $422 and $2,174 of costs allocated from RSL, RSI, and RSG during the six months ended September 30, 2019 and 2018, respectively. Also includes share-based compensation expense (see Note 10).